NCT06525220 2026-04-22
A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)
Merus B.V.
Phase 3 Recruiting
Clinical Trials
10 trialsNCT02128906 2026-04-16
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
University of Pittsburgh
Phase 2 Recruiting
NCT07419464 2026-04-09
5-Fluorouracil Response and Optimization STudy (The FROST Trial)
Washington University School of Medicine
Phase 2 Not yet recruiting
NCT06788990 2026-03-23
FORTIFI-HN01
Bicara Therapeutics
Phase 2/3 Recruiting
NCT01647477 2026-03-13
DEREDIA
Centre Oscar Lambret
Phase NA Terminated
NCT04590963 2026-03-13
INTERLINK-1
AstraZeneca
Phase 3 Active not recruiting
NCT05199584 2026-03-05
A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations
Endeavor Biomedicines, Inc.
Phase 2 Completed
NCT03656133 2026-02-20
Use of a Proliferation Saturation Index to Determine Personalized Radiotherapy for HPV + Oropharyngeal Cancers
H. Lee Moffitt Cancer Center and Research Institute
Phase NA Completed
NCT05386550 2026-02-19
Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants (XRAY VISION)
EMD Serono
Phase 3 Terminated
NCT04368702 2026-02-09
CONFIRM
Brigham and Women's Hospital
Phase NA Recruiting